Christine Peters, Specialist Registrar in Medical Microbiology, Southern General Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK
A normally fit and well 31-year-old man presented to the emergency department with a severe headache of nine days duration. He had a Glasgow Coma Scale (GCS) of 15, expressive dysphasia and a mild right facial weakness, but was apyrexial and normotensive.
Sarah Whitehead, Consultant in Medical Microbiology, Southern General Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK
A previously well 51-year-old woman underwent neurosurgery for a subarachnoid haemorrhage. Recovery was complicated by hydrocephalus, necessitating insertion of an external ventricular drain.
Xeomin (incobotulinumtoxinA) filed with FDA for treatment of upper limb spasticity- Merz
Musculoskeletal Disorders Drug News yesterday
Merz Neurosciences, a division of Merz North America, has submitted an sBLA to the FDA to seek approval for the...
BioMarin acquires world rights to Kuvan (sapropterin dihydrochloride), excluding Japan, and to pegvaliase from Merck Serono as treatments for PKU
Medical Genetics Drug News 2 days ago
BioMarin Pharmaceutical has announced that it has acquired all global rights to Kuvan (sapropterin dihydrochloride) and pegvaliase from Merck Serono....
Advanced Accelerator Applications announces Phase III positive results for Lutathera (177Lu-DOTATATE) to treat neuroendocrine tumours
Oncology Drug News 3 days ago
Advanced Accelerator Applications announced today at ECC 2015 that the pivotal Phase III NETTER-1 study for Lutathera (177Lu-DOTATATE) met its...
Phase III positive results from ORATORIO trial of ocrelizumab in primary progressive multiple sclerosis- Genentech + Roche
Neurological Disorders Drug News 5 days ago
Genentech has announced positive results from a pivotal Phase III study that evaluated the investigational medicine ocrelizumab in patients with...
CHMP recommends Numient (levodopa-carbidopa modified release) for Parkinsons disease- Impax
Neurological Disorders Drug News 5 days ago
Impax Laboratories, Inc.announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted...
Bob Bury muses on the state of modern mental healthcare. Instead of asylums, patients are now part of the community. But what of those who fall through the cracks? How can GPs help patients who need emergency mental health care? Can we learn anything from the methods of the past? Are three letter acronyms helpful? Examining the politics and hurdles of the UK's modern Community Mental Health provision, Bob Bury questions what UK healthcare professionals can do better and how things should change.
BACKGROUND: Although levodopa is the most common drug prescribed to relieve the symptoms of Parkinson's disease it is associated with motor and psychiatric side-effects. Consequently, interest ...
IMPORTANCE: Parkinson disease is the second most common neurodegenerative disease worldwide. Although no available therapies alter the underlying neurodegenerative process, symptomatic therapies ...
European Stroke Organisation (ESO) guidelines for the management of temperature in patients with acute ischemic strokeJul 2015
Hyperthermia is a frequent complication in up to 50% of patients with acute ischemic stroke, and it..
This guideline provides recommendations based on current evidence for best practice in the..
This activity covers the red flag symptoms that may alert the physician to a more serious cause of persistent headache.
In "Management of Migraine in Adults" physicians will learn to apply evidence-based approaches in the diagnosis and management of migraine headache and compare current approach to treatment at the state...
After completing this module you should know: what the common disorders of speech and language in adults are, in particular, aphasia (dysphasia), dysarthria, and apraxia (dyspraxia), what the fundamental differences...
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia ...
A Phase 3 Study to Examine the Efficacy, Safety and Tolerability of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's DiseaseMon 01 Jun 2015
A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to ...